Zobrazeno 1 - 10
of 236
pro vyhledávání: '"Chau T. Dang"'
Autor:
Whitney P. Underwood, Meghan G. Michalski, Catherine P. Lee, Gina A. Fickera, Su S. Chun, Stefan E. Eng, Lydia Y. Liu, Brandon L. Tsai, Chaya S. Moskowitz, Jessica A. Lavery, Kimberly J. Van Zee, Ginger J. Gardner, Jennifer J. Mueller, Chau T. Dang, Behfar Ehdaie, Vincent P. Laudone, James A. Eastham, Jessica M. Scott, Paul C. Boutros, Lee W. Jones
Publikováno v:
npj Digital Medicine, Vol 7, Iss 1, Pp 1-13 (2024)
Abstract We developed and evaluated the Digital Platform for Exercise (DPEx): a decentralized, patient-centric approach designed to enhance all aspects of clinical investigation of exercise therapy. DPEx integrated provision of a treadmill with telem
Externí odkaz:
https://doaj.org/article/3fdc110cc5ab46459ab440e7fbb9ba22
Autor:
Nicholas Mai, Carlos H. dos Anjos, Pedram Razavi, Anton Safonov, Sujata Patil, Yuan Chen, Joshua Z. Drago, Shanu Modi, Jacqueline F. Bromberg, Chau T. Dang, Dazhi Liu, Larry Norton, Mark Robson, Sarat Chandarlapaty, Komal Jhaveri
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-9 (2024)
Abstract After disease progression on endocrine therapy (ET) plus a CDK4/6 inhibitor, there is no standardized sequence for subsequent treatment lines for estrogen receptor positive (ER+) metastatic breast cancer (MBC). CDK4/6i retrial as a treatment
Externí odkaz:
https://doaj.org/article/88f817264c2f476b8cdad0ce4fa3f038
Autor:
Anthony F. Yu, Chau T. Dang, Justine Jorgensen, Chaya S. Moskowitz, Patricia DeFusco, Eric Oligino, Kevin C. Oeffinger, Jennifer E. Liu, Richard M. Steingart
Publikováno v:
Cardio-Oncology, Vol 9, Iss 1, Pp 1-6 (2023)
Abstract Background Echocardiograms are recommended every 3 months in patients receiving human epidermal growth factor 2 (HER2)-targeted therapy for surveillance of left ventricular ejection fraction (LVEF). Efforts to tailor treatment for HER2-posit
Externí odkaz:
https://doaj.org/article/de848bdfc40e4f2097621af902c0a542
Autor:
Anthony F. Yu, I‐Hsin Lin, Justine Jorgensen, Robert Copeland‐Halperin, Stephanie Feldman, Ishmam Ibtida, Amare Assefa, Michelle N. Johnson, Chau T. Dang, Jennifer E. Liu, Richard M. Steingart
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 12, Iss 19 (2023)
Background Cancer therapy–related cardiac dysfunction (CTRCD) is an important treatment‐limiting toxicity for patients with human epidermal growth factor receptor 2 (HER2)–positive breast cancer that adversely affects cancer and cardiovascular
Externí odkaz:
https://doaj.org/article/edcd3fe40d4d49c58c412093a6d13af0
Autor:
Mark Pegram, Richard Pietras, Chau T. Dang, Rashmi Murthy, Thomas Bachelot, Wolfgang Janni, Priyanka Sharma, Erika Hamilton, Cristina Saura
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Breast cancer (BC) with expression of the estrogen receptor (ER) and/or progesterone receptor (PR) protein and with overexpression/amplification of the human epidermal growth factor receptor 2 (HER2), termed hormone receptor-positive (HR+)/HER2+ BC,
Externí odkaz:
https://doaj.org/article/24916589e93a4cc888c0fccb568d1c08
Autor:
Emanuela Ferraro, Jasmeet Singh, Sujata Patil, Pedram Razavi, Shanu Modi, Sarat Chandarlapaty, Andrea V. Barrio, Rachna Malani, Ingo K. Mellinghoff, Adrienne Boire, Hannah Y. Wen, Edi Brogi, Andrew D. Seidman, Larry Norton, Mark E. Robson, Chau T. Dang
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-8 (2022)
Abstract The addition of pertuzumab (P) to trastuzumab (H) and neoadjuvant chemotherapy (NAC) has decreased the risk of distant recurrence in early stage HER2-positive breast cancer. The incidence of brain metastases (BM) in patients who achieved pat
Externí odkaz:
https://doaj.org/article/5efc975ad4074b27a5124e022f559502
Autor:
Joseph A. Sparano, Anne O’Neill, Noah Graham, Donald W. Northfelt, Chau T. Dang, Antonio C. Wolff, George W. Sledge, Kathy D. Miller
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-6 (2022)
Abstract Systemic inflammation is believed to contribute to the distant recurrence of breast cancer. We evaluated serum samples obtained at diagnosis from 249 case:control pairs with stage II-III Her2-negative breast cancer with or without subsequent
Externí odkaz:
https://doaj.org/article/3741cea676a84aada2335dfb8178147f
Autor:
Anthony F. Yu, MD, Chaya S. Moskowitz, PhD, Katherine Lee Chuy, MD, Ji Yang, MD, Chau T. Dang, MD, Jennifer E. Liu, MD, Kevin C. Oeffinger, MD, Richard M. Steingart, MD
Publikováno v:
JACC. CardioOncology, Vol 2, Iss 2, Pp 166-175 (2020)
Background: Guidelines recommend left ventricular ejection fraction (LVEF) assessments every 3 months for cardiotoxicity monitoring during human epidermal growth factor receptor 2 (HER2) targeted therapy. Evidence in support of this practice is lacki
Externí odkaz:
https://doaj.org/article/718f7b62478341409f1af3fdaaba9c1b
Publikováno v:
JACC. CardioOncology, Vol 1, Iss 1, Pp 11-13 (2019)
Externí odkaz:
https://doaj.org/article/c81d004acde740f796504e68ce14d0ce
Autor:
Sara M Tolaney, Paolo Tarantino, Noah Graham, Nabihah Tayob, Laia Parè, Guillermo Villacampa, Chau T Dang, Denise A Yardley, Beverly Moy, P Kelly Marcom, Kathy S Albain, Hope S Rugo, Matthew J Ellis, Iuliana Shapira, Antonio C Wolff, Lisa A Carey, Romualdo Barroso-Sousa, Patricia Villagrasa, Michelle DeMeo, Molly DiLullo, Jorge Gomez Tejeda Zanudo, Jakob Weiss, Nikhil Wagle, Ann H Partridge, Adrienne G Waks, Clifford A Hudis, Ian E Krop, Harold J Burstein, Aleix Prat, Eric P Winer
Publikováno v:
The Lancet Oncology. 24:273-285
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f44b54dbee330cc4378e80a16fc9c58c
https://doi.org/10.1016/s1470-2045(23)00051-7
https://doi.org/10.1016/s1470-2045(23)00051-7